Information Provided By: 
Fly News Breaks for December 14, 2018
CPRX
Dec 14, 2018 | 07:06 EDT
H.C. Wainwright analyst Andrew Fein raised his price target for Catalyst Pharmaceuticals to $9 and reiterates a Buy rating on the shares. A key update on yesterday's commercialization call of Firdapse is pricing, Fein tells investors in a research note. He points out that the announced $375,000 annual cost of Firdapse for the treatment of Lambert-Eaton myasthenic syndrome is much higher than what he previously assumed. Given Catalyst's market cap of ~$250M, the analyst thinks there is "still plenty of room for the stock to appreciate."
News For CPRX From the Last 2 Days
There are no results for your query CPRX
